Amgen Gets $70M In Biosimilar Patent Suit Against Hospira
Law360, Wilmington (September 22, 2017, 10:21 PM EDT) -- A Delaware federal jury awarded Amgen Inc. $70 million in damages late Friday after finding that Hospira Inc. infringed a patent for the anemia treatment Epogen, rejecting Hospira's argument that it was protected by a safe harbor meant for companies seeking federal approval for biosimilar products.
After five hours of deliberation, the jury found that Hospira infringed Amgen's patent that covers the creation of specialized erythropoietin protein cells, or EPO, that stimulate the creation of red blood cells in anemia patients. (AP) After five hours of deliberation, the jury found that Hospira infringed Amgen’s patent that covers the creation of specialized...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!